Tempus AI to Acquire Personalis in $1.5 Billion Genomics Expansion

The transaction values the enterprise at $1.5 billion, net of Tempus’s existing holdings, with shareholders set to receive $16.25 per share in stock. While the final exchange ratio will be determined closer to the anticipated closing date in late 2026 or early 2027, Tempus retains the flexibility to settle up to half of the total consideration in cash.

This move formalizes a relationship that began in 2023, when the two companies launched a partnership to commercialize the NeXT Personal minimal-residual-disease test. By combining its multimodal data platform and AI-driven oncology portfolio with the specialized monitoring tools developed by Personalis, Tempus aims to accelerate biomarker discovery and expand access to longitudinal cancer care. Trading of Personalis shares was halted premarket on Monday following the announcement.